Navigation Links
Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company

COPENHAGEN and OSLO, March 4 /PRNewswire/ -- Pharmexa A/S and Affitech AS announced today that they have entered into a conditional agreement to merge the two companies by means of a share for share acquisition by Pharmexa A/S of the private Norwegian company, Affitech AS. The purpose of the merger is to transform Pharmexa from a cancer and infectious disease vaccine business into a company focused on the research and development of human antibody therapeutic drugs.

Under the terms of the merger agreement, Pharmexa will offer to acquire 100% of the outstanding and issued share capital of Affitech AS in exchange for newly issued shares in Pharmexa. On completion of the transaction, Affitech shareholders will own approximately 70% and Pharmexa shareholders 30% of the merged Company. The combined Company will be renamed Affitech A/S and it is the aim to continue the Company's listing on the Nasdaq OMX exchange in Copenhagen. The existing Affitech drug discovery business in Oslo will be renamed Affitech Research AS.

As part of the merger certain Affitech shareholders will undertake to participate in a new share issue which Pharmexa expects to take place during Q2 or Q3 2009.

Aims of the Merger

The acquisition of Affitech by Pharmexa is intended to create a new European biopharmaceutical company listed on the Nasdaq OMX Copenhagen exchange dedicated to the discovery and development of human antibody therapeutics in cancer and other diseases of unmet medical need. The integration of the two companies marks a transformational event by combining the antibody discovery expertise and early product pipeline of Affitech with the drug development capabilities, processes and infrastructure of Pharmexa. The combined Company will focus its activities entirely in the field of human antibody therapeutics. Antibodies constitute one of the most commercially successful fields in the biotechnology sector.

Announcing the merger, Dr. Achim Kaufhold, CEO of Pharmexa said: "Pharmexa has experienced product setbacks over the last year which have led us to consider a variety of strategic options to revitalise the business and to generate future value for our shareholders. The acquisition of Affitech builds on the expertise and capabilities of Pharmexa, but is also a transformational event that moves us into the exciting field of antibody therapeutics, one of the most attractive sectors of the biopharmaceutical industry.

Following several high value mergers and acquisitions in the antibody discovery field, Affitech remains one of only a limited number of independent companies with a strong position in high throughput screening of antibody libraries. Meanwhile, there is an increasing demand for antibody therapeutics as pipeline products from major pharma companies. This transaction will create a technology innovator and product developer that is expected to be able to meet this demand for new antibody therapeutics at all levels-from discovery through to clinical stage products. The acquisition of Affitech is intended to be the first step in creating a leading new Company in the antibody field with the potential for sustained growth in shareholder value".

Dr. Martin Welschof, CEO of Affitech, also commented: "Affitech has developed a fully integrated antibody discovery platform consisting of human antibody libraries with high functionality, based on phagemid display technology plus several screening technologies with high degree of versatility. Through partnerships with both pharma and biotech businesses, we have demonstrated that this platform is highly productive in identifying competitive new antibody drugs. As a direct result of the merger, Affitech will have the capability for the first time to develop its own antibody products through human clinical trials."


    Claude Mikkelsen
    Senior Vice President
    Finance & Investor Relations,
    Tel. +45-4516-2525 or +45-4060-2558

    Achim Kaufhold
    Chief Executive Officer,
    Tel +45-4516-2525

    Martin Weschof
    Chief Executive Officer,
    Tel. +47-22-95-88-77

SOURCE Affitech AS
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Affitech Acquires Pharmexas Diabody Technology
2. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
3. Affitech Appoints Dr. Keith McCullagh as Chairman
4. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
5. The New MACSQuant(TM) Analyzer Combines Cell Enrichment and Flow Cytometry
6. Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies
7. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
8. Old and new therapies combine to tackle atherosclerosis
9. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
10. Elseviers Engineering Village Search Platform Combines the American Geological Institutes Georef Database With Google Maps
11. Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem ... and aesthetics professionals from Central America and abroad for the first Iberoamerican Convention ... Panama Feb. 17-19, 2016. Testart will present and discuss new trends in anti-aging ...
(Date:11/30/2015)... ... ... Group announced the opening of a new core patient care hub with the opening ... facilities are part of GSCG’s expansion efforts in Latin America. , Both the Arica ... patients from around the world. , The clinics will be headed by Victor Perez, M.D. ...
(Date:11/30/2015)... Partnership includes an MPP licen ... niversity , s Solid Drug Nanoparticle (SDN) Technology ... up through cost cuts of priority ... licensees based anywhere in the world will have the right to make, use and ... , where licensees based anywhere in the world will have the right to make, ...
(Date:11/30/2015)... Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that ... its Board of Directors to replace Dr. Peter Johann ... experience as co-founder of Resverlogix, with expertise in the fields ... --> Dr. Wong remarked, "I am very excited ... standing expertise in epigenetics and the advanced stage of the ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):